已发表论文

当归少药散通过抑制海马神经元凋亡改善阿尔茨海默病的血清药理学研究

 

Authors Zhang KX, Zhang JW, Jiang YH, Wang YR, Liu ZL, Ding PL, Wang XY, Cui WQ, Xu XQ, Wang YH 

Received 9 October 2024

Accepted for publication 15 January 2025

Published 10 February 2025 Volume 2025:19 Pages 911—929

DOI https://doi.org/10.2147/DDDT.S490900

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Yan Zhu

Kai-Xin Zhang,1 Ji-Wei Zhang,2 Yan-Hong Jiang,1 Yi-Ran Wang,1 Zhen-Ling Liu,1 Peng-Li Ding,1 Xiang-Ying Wang,1 Wen-Qiang Cui,3 Xiang-Qing Xu,3,* Ya-Han Wang3,* 

1First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, 250000, People’s Republic of China; 2College of Acupuncture and Massage, Shandong University of Traditional Chinese Medicine, Jinan, 250000, People’s Republic of China; 3Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250000, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Xiang-Qing Xu, Ya-Han Wang; Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250000, People’s Republic of China, Email happyxiangqing@163.com; sdwangyahan@sina.com

Background: Danggui-Shaoyao-San (DSS) is a traditional Chinese medicine prescription with a history of nearly 2000 years, originally widely used for gynecological diseases, and in recent years research has found that DSS also has a good therapeutic effect on Alzheimer’s disease (AD).
Purpose: The objective is to investigate the metabolic components of the DSS in the blood and the potential mechanisms for AD.
Materials and Methods: Liquid chromatography‒mass spectrometry (LC-MS) combined with gas chromatography‒mass spectrometry (GC-MS) based non-targeted metabolomics were used to conduct in-depth research. Serum Pharmacology was used to analyze potential mechanisms of DSS for AD. C57BL/6J mice and Hippocampal neuronal cell line (HT-22) were used to prepare the AD model. Enzyme linked immunosorbent assay (Elisa), quantitative polymerase chain reaction (q-PCR), Morris water maze,Western blot (WB), Immunohistochemical and Immunofluorescence were used to study the effect of DSS on AD. Flow cytometry and Cell Counting Kit-8 (CCK-8) reveal the effect of DSS serum on HT-22 proliferation and apoptosis.
Results: A total of 57 metabolic components were screened in DSS serum. Serum Pharmacology revealed that the calcium signaling pathway and cAMP/PKA/CREB pathway may be a potential mechanism through which DSS treated AD. DSS can reduce aberrant phosphorylation of Tau and modulates cAMP/PKA/CREB pathway to improve cognition and apoptosis in AD mice. DSS serum can increase the cell viability of HT-22 and reduce apoptosis mainly by alleviating mitochondrial calcium overloading.
Conclusion: DSS can modulate the calcium signaling pathway and enhance the cAMP/PKA/CREB signaling pathway to ameliorate Tau aberrant phosphorylation, cognitive deficits and neuronal apoptosis after AD.

Keywords: Alzheimer’s disease, calcium signaling pathway, cAMP/PKA/CREB signaling pathway, Danggui-Shaoyao-San, apoptosis, serum pharmacology